Updated recommendations include:

**Eligible Population**
*Adults with suspected heart failure, with reduced ejection fraction*

**Evaluation:**
- Initial assessment – no change

**Adults with heart failure with reduced ejection fraction**

**Management:**
- Recommended for routine use
  - ACE inhibitors or angiotensin receptor blocker/neprilysin inhibitor (AR/NI) or ARB’s in all patients, unless contraindicated\(^1\), but drugs from these classes should not be used together

- Recommended for use in *select* patients
  - Ivabradine for patients with symptomatic HF, LVEF <35%, on maximally tolerated (or target) beta blocker dose, in sinus rhythm with rate >70 bpm, and if hospitalized within the last year
  - Consider referral for evaluation for implantable defibrillator in patients with LVEF <35% and either symptomatic heart failure or ischemic cardiomyopathy

---

\(^1\) Contraindications include: life-threatening adverse reactions (angioedema or anuric renal failure), pregnancy, hypotensive patients at immediate risk of cardiogenic shock, systolic blood pressure <80 mm Hg, serum creatinine >3 mg/dL, bilateral renal artery stenosis, or serum potassium >5.5 mmol/L.